ReviewFrontiers in bioengineering and biotechnology2015
On the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug Monitoring.
Review in Frontiers in bioengineering and biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current Challenges.Therapeutic drug monitoring · 2026Review
- Plasmonic Brownian Ratchets for Directed Transport of Analytes.Nano letters · 2026Article
- Development of an automated device and mobile application for digoxin detection and quantification from dried blood spots using gold-coated magnetic nanoprobes and the lateral-flow immunoassay.Analytical and bioanalytical chemistry · 2025Article
- Advances in Psychotropic Treatment for Pregnant Women: Efficacy, Adverse Outcomes, and Therapeutic Monitoring.Journal of clinical medicine · 2024Review
- Progress on Electrochemical Sensing of Pharmaceutical Drugs in Complex Biofluids.Chemosensors (Basel, Switzerland) · 2023Article
- Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests.Analytical and bioanalytical chemistry · 2022Review
- The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib.Frontiers in pharmacology · 2020Review
- Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecanChemical science · 2019Article
- Novel technologies in detection, treatment and prevention of substance use disorders.Journal of food and drug analysis · 2019Review
- The Use of Metabolomics and Inflammatory Mediator Profiling Provides a Novel Approach to Identifying Pediatric Appendicitis in the Emergency Department.Scientific reports · 2018Article
- Saliva as a Future Field in Psoriasis Research.BioMed research international · 2018Review
- Bioluminescent Antibodies for Point-of-Care Diagnostics.Angewandte Chemie (International ed. in English) · 2017Article
- Potential of Surface Enhanced Raman Spectroscopy (SERS) in Therapeutic Drug Monitoring (TDM). A Critical Review.Biosensors · 2016Review
- Integrating Cell Phone Imaging with Magnetic Levitation (i-LEV) for Label-Free Blood Analysis at the Point-of-Living.Small (Weinheim an der Bergstrasse, Germany) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advancements in point-of-care (PoC) technologies show great transformative promises for personalized preventative and predictive medicine. However, fields like therapeutic drug monitoring (TDM), that first allowed for personalized treatment of patients' disease, still lag behind in the widespread application of PoC devices for monitoring of patients. Surprisingly, very few applications in commonly monitored drugs, such as anti-epileptics, are paving the way for a PoC approach to patient therapy monitoring compared to other fields like intensive care cardiac markers monitoring, glycemic controls in diabetes, or bench-top hematological parameters analysis at the local drug store. Such delay in the development of portable fast clinically effective drug monitoring devices is in our opinion due more to an inertial drag on the pervasiveness of these new devices into the clinical field than a lack of technical capability. At the same time, some very promising technologies failed in the clinical practice for inadequate understanding of the outcome parameters necessary for a relevant technological breakthrough that has superior clinical performance. We hope, by over-viewing both TDM practice and its yet unmet needs and latest advancement in micro- and nanotechnology applications to PoC clinical devices, to help bridging the two communities, the one exploiting analytical technologies and the one mastering the most advanced techniques, into translating existing and forthcoming technologies in effective devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.